Literature DB >> 14609248

The causes of underdiagnosing akathisia.

Shigehiro Hirose1.   

Abstract

This article reviews what causes clinicians to overlook or underdiagnose akathisia. The causes are considered to be related to both the patient's symptoms and the clinician's attitude toward akathisia. The patient factors include mild severity of akathisia, lack of apparent motor restlessness, no voluntary expression of inner restlessness, no clear communication of inner restlessness, restlessness in body parts other than the legs, atypical expressions of inner restlessness, other prominent psychic symptoms, and absence of other extrapyramidal signs. The clinician factors include emphasis on objective restlessness, failure to consider akathisia during antipsychotic therapy, failure to fully implement antiakathisia treatments in ambiguous cases, and strict adherence to research diagnostic criteria. Akathisia is likely to be overlooked or underdiagnosed when both patient and clinician factors are present. Currently, there may be two major problems with underdiagnosis: (1) symptoms that fulfill the diagnostic criteria for akathisia are overlooked, and (2) conditions that do not fulfill the diagnostic criteria but can still benefit from antiakathisia measures are underdiagnosed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609248     DOI: 10.1093/oxfordjournals.schbul.a007027

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  10 in total

Review 1.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

2.  Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics.

Authors:  Yu-Jung Wei; Xinyue Liu; Nikhil Rao; Marie McPherson; Mary Beth Jones; Regina Bussing; Almut G Winterstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-07-14       Impact factor: 2.576

3.  Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.

Authors:  Koen Demyttenaere; Johan Detraux; Giorgio Racagni; Kristof Vansteelandt
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

4.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

Review 5.  The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis.

Authors:  Jennifer E Thomas; Joshua Caballero; Catherine A Harrington
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 6.  Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.

Authors:  Haitham Salem; Caesa Nagpal; Teresa Pigott; Antonio Lucio Teixeira
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

7.  "Phantom akathisia" in an amputated leg of a sarcoma patient: a case report.

Authors:  Mayumi Ishida; Jungo Imanishi; Yasuo Yazawa; Yu Sunakawa; Tomoaki Torigoe; Hideki Onishi
Journal:  Biopsychosoc Med       Date:  2020-03-07

8.  Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depression.

Authors:  Thomas M Penders; Salina Agarwal; Rachel Rohaidy
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-04       Impact factor: 2.570

9.  A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study.

Authors:  Peter J Weiden; Raymond Manning; Curt D Wolfgang; J Michael Ryan; Linda Mancione; Guangyang Han; Saeed Ahmed; Mallery G Mayo
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

10.  Comments on Lucire and Crotty, 2011.

Authors:  Anton Jm Loonen; Robbert-Jan Verkes
Journal:  Pharmgenomics Pers Med       Date:  2016-08-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.